^
    20h
    A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) (clinicaltrials.gov)
    P2, N=150, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2029 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    20h
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    22h
    A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, West China Hospital
    New P2 trial • Checkpoint inhibition
    |
    Anniko (penpulimab-kcqx) • Meiyouheng (becotatug vedotin) • Yidafan (ivonescimab) • becotarug (JMT101)
    1d
    Ablation of cancer cell secreted neuropeptide PTHLH/PTHrP provokes anti-tumor immunity in murine tongue squamous cell carcinoma. (PubMed, Sci Rep)
    Moreover, these tumors also showed lower expression of tumor proliferative and neuron markers. Together these findings established cancer cell secreted PTHLH as a critical mediator of immunosuppression and neuron infiltrations in HNSCC, particularly in tongue tumor.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • PTHLH (Parathyroid Hormone Like Hormone)
    |
    PD-L1 expression
    1d
    Feasibility and diagnostic accuracy of a capsule-sponge device for esophageal squamous neoplasia (EDEN trial). (PubMed, Clin Gastroenterol Hepatol)
    In this case-enriched cohort, the capsule-sponge was safe and feasible, and cytology with adjunct p53-IHC showed high accuracy for ESN/early ESCC. Validation in asymptomatic high-risk cohorts is warranted to define real-world performance and triage utility (NCT04192695).
    Journal
    |
    TP53 (Tumor protein P53)
    1d
    OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    BS001 • BS006
    1d
    Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    1d
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=46, Recruiting, AstraZeneca | N=162 --> 46 | Trial completion date: Aug 2039 --> Jul 2029
    Enrollment change • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    1d
    Tannic acid-modified graphene oxide nanoplatform incorporating bortezomib as a combination chemo- and NIR-mediated photothermal oral cancer therapy. (PubMed, Colloids Surf B Biointerfaces)
    Moreover, in vivo studies in MOC2-induced tumor-bearing mice demonstrated a significant upregulation of ER stress markers, including PERK and PDI, as well as remodeling of macrophages, characterized by the upregulation of M1 markers, such as iNOS, TNF-α, and CD86. Thus, BTZ@GOT is an efficient nanotherapy that warrants further exploration for the treatment of oral carcinoma.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)
    |
    bortezomib
    1d
    Solitary Fibrous Tumor of the Oropharyngeal Lateral Wall: A Case Report and Review of Diagnostic and Therapeutic Challenges. (PubMed, Cureus)
    This report highlights the challenges in diagnosing and treating oropharyngeal SFTs. It emphasizes the need for molecular confirmation and adds to the limited research on SFTs in rare head and neck locations.
    Journal
    |
    STAT6 (Signal transducer and activator of transcription 6)
    1d
    NIR-II biomimetic nanoplatform optogenetic CD274 editing of HNSCC immunogenicity for enhanced photoimmunotherapy. (PubMed, Mater Today Bio)
    Moreover, the mild photothermal therapeutic effect of ARPC simultaneously induced immunogenic cell death in tumor cells for enhancing CD8+ T cell infiltration and proliferation, and thereby leading to photoimmunotherapy. This study provides an NIR-II optogenetic CRISPR/Cas9 CD274 for editing reprogrammed photo-immunogenic therapy strategy, showing great clinical potential for overcoming the low immunogenicity of HNSCC.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    1d
    Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy. (PubMed, EXCLI J)
    See also the graphical abstract(Fig. 1).
    Review • Journal • IO biomarker
    |
    FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3)